1. Moreno-Sanz G. Can you pass the acid test? Critical review and novel therapeutic perspectives of Δ9-tetrahydrocannabinolic acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. 2. McPartland JM, MacDonald C, Young M, et al. Affinity and efficacy studies of tetrahydrocannabinolic acid A at cannabinoid receptor types one and two. Cannabis Cannabinoid Res. 2017;2(1):87-95. 3. De Petrocellis L, Ligresti A, Schiano Moriello A, et al. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol. 2013;168(1):79-102. 4. Verhoeckx KCM, Korthout HAAJ, van Meeteren-Kreikamp AP, et al. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol. 2006;6(4):656-665. 5. Nallathambi R, Mazuz M, Ion A, et al. Anti-inflammatory activity in colon models is derived from Δ9-tetrahydrocannabinolic acid that interacts with additional compounds in cannabis extracts. Cannabis Cannabinoid Res. 2017;2(1):167-182. 6. Nadal X, del Río C, Casano S, et al. Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity. Br J Pharmacol. 2017;174(23):4263-4276. 7. Obata K, Katsura H, Mizushima T, et al. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. J Clin Invest. 2005;115(9):2393-2401. 8. Akopian AN, Ruparel NB, Patwardhan A, et al. Cellular/molecular cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J Neurosci. 2008;28(5):10641-11075. 9. Andersson DA, Gentry C, Alenmyr L, et al. TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Δ9-tetrahydrocannabiorcol. Nat Commun. 2011;2(1):551. 10. De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163(7):1479-1494. 11. De Petrocellis L, Vellani V, Schiano-Moriello A, et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther. 2008;325(3):1007-1015. 12. Griggs RB, Donahue RR, Adkins BG, et al. Pioglitazone inhibits the development of hyperalgesia and sensitization of spinal nociresponsive neurons in type 2 diabetes. J Pain. 2016;17(3):359-373. 13. Ruhaak LR, Felth J, Karlsson PC, et al. Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biol Pharm Bull. 2011;34(5):774-778. 14. Kato M, Nishida S, Kitasato H, et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol. 2001;53(12):1679-1685. 15. Blanco FJ, Guitian R, Moreno J, et al. Effect of anti-inflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999;26(6):1366-1373. 16. Rock EM, Kopstick RL, Limebeer CL, et al. Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. Br J Pharmacol. 2013;170(3):641-648. 17. Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49-52. 18. Moldzio R, Pacher T, Krewenka C, et al. Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures. Phytomedicine. 2012;19(8-9):819-824. 19. Health Canada. Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids. https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/marihuana/med/ infoprof-eng.pdf. Accessed May 10, 2018. 20. Government of Canada. Canabis Market Data. https://www.canada.ca/en/health-canada/ services/drugs-medication/cannabis/licensed-producers/market-data.html. Accessed October 12, 2018. 21. Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 011;23:891-896. 22. Toth C, Mawani S, Brady S, et al. An enriched- enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain. 2012;153:2073-2082. 23. Machado Rocha FC, Stefano SC, De Cassia HR, et al. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl). 2008;17:431-443. 24. Aragona M, Onesti E, Tomassini V, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol. 2009;32:41-47. 25. Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012;184:1143-1150. 26. Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006;12:639-645. 27. Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14:290-296. 28. Kelly TH, Foltin RW, and Fischman MW. Effects of smoked marijuana on heart rate, drug ratings and task performance by humans. Behav Pharmacol. 1993;4:167-178. 29. Fiz J, Duran M, Capella D, et al. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS One. 2011;6:e18440. 30. Sidney S. Cardiovascular consequences of marijuana use. J Clin Pharmacol. 2002;42:64S-70S. 31. Fried PA. Conceptual issues in behavioral teratology and their application in determining long-term sequelae of prenatal marihuana exposure. J Child Psychol Psychiatry. 2002;43:81-102. 32. Richardson GA, Ryan C, Willford J, et al. Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. Neurotoxicol Teratol. 2002;24:309-320. 33. El-Marroun H, Tiemeier H, Steegers EA, et al. Intrauterine cannabis exposure affects fetal growth trajectories: the generation R study. J Am Acad Child Adolesc Psychiatry. 2009;48:1173-1181. 34. Perez-Reyes M and Wall ME. Presence of delta9-tetrahydrocannabinol in human milk. N Engl J Med. 1982;307:819-820. 35. Ahmad GR and Ahmad N. Passive consumption of marijuana through milk: a low level chronic exposure to delta-9-tetrahydrocannabinol (THC). J Toxicol Clin Toxicol. 1990;28:255-260. 36. Astley SJ and Little RE. Maternal marijuana use during lactation and infant development at one year. Neurotoxicol Teratol. 1990;12:161-168. 37. Asbridge M, Hayden JA, and Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ. 2002;344:e536. 38. Bosker WM, Kuypers KP, Theunissen EL, et al. Medicinal Delta(9)-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. Addiction. 2012;107:1837-1844. 39. Kuypers KP, Legrand SA, Ramaekers JG, et al. A case-control study estimating accident risk for alcohol, medicines and illegal drugs. PLoS One. 2012;7:e43496. 40. Institute of Medicine. First, do no harm: consequences of marijuana use and abuse. Marijuana and medicine: Assessing the science base. Joy JE, Watson SJ, and Benson JA. Washington, DC: National Academy Press, 1999. 41. Mittleman MA and Mostofsky E. Physical, psychological and chemical triggers of acute cardiovascular events: preventive strategies. Circulation. 2011;124:346-354. 42. Vandrey R and Haney M. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs. 2009;23:543-553. 43. Hall W and Solowij N. The adverse health and psychological consequences of cannabis dependence. Cannabis dependence. Roffman RA and Stephens RS. Cambridge: Cambridge University Press, 2006. 44. Cooper ZD and Haney M. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol. 2008;13:188-195. 45. van Rossum I, Boomsma M, Tenback D, et al. Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. J Nerv Ment Dis. 2009;197:35-40. 46. Kuepper R, van Os J, Lieb R, et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011;342:d738. 47. Yamaori S, Kushihara M, Yamamoto I, et al. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol. 2010;79:1691-1698. 48. Sachse-Seeboth C, Pfeil J, Sehrt D, et al. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther. 2009;85:273-276. 49. Baron, Eric P. 2018. "Medicinal Properties of Cannabinoids , Terpenes , and Flavonoids in Cannabis , and Benefits in Migraine , Headache , and Pain: An Update on Current Evidence and Cannabis Science." Headache Currents July/August: 1139–86.